UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
PTIX holding history
Protagenic Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
PTIX overviewAll 13F holders of PTIXFull Q2 2026 holdings
- Shares (Q4 2025)
- 0
- Sold out in Q4 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 13
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2025 | 0 | $0 | 0.0% | −56−100.0% | Sold out | Holders |
| Q3 2025 | 56 | $192 | <0.1% | −8,964−99.4% | Reduced | Holders |
| Q2 2025 | 9,020 | $32.9K | <0.1% | +9,020 | New | Holders |
| Q1 2025 | 0 | $0 | 0.0% | −14,414−100.0% | Sold out | Holders |
| Q4 2024 | 14,414 | $7.06K | <0.1% | +4,674+48.0% | Added | Holders |
| Q3 2024 | 9,740 | $6.11K | <0.1% | −338−3.4% | Reduced | Holders |
| Q2 2024 | 10,078 | $9.12K | <0.1% | +10,078 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −305−100.0% | Sold out | Holders |
| Q1 2023 | 305 | $528 | <0.1% | −3,983−92.9% | ReducedConverted for a 1-for-4 split | Holders |
| Q4 2022 | 17,153 | $6.86K | <0.1% | +10,676+164.8% | Added | Holders |
| Q3 2022 | 6,477 | $4.00K | <0.1% | +5,457+535.0% | Added | Holders |
| Q2 2022 | 1,020 | $1.00K | <0.1% | −1,373−57.4% | Reduced | Holders |
| Q1 2022 | 2,393 | $2.00K | <0.1% | −3,132−56.7% | Reduced | Holders |
| Q4 2021 | 5,525 | $8.00K | <0.1% | +286+5.5% | Added | Holders |
| Q3 2021 | 5,239 | $10.0K | <0.1% | +2,227+73.9% | Added | Holders |
| Q2 2021 | 3,012 | $9.00K | <0.1% | +3,012 | New | Holders |